HCA Healthcare, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Ryan Langston from TD Cowen maintained a Buy rating on the stock and has a $500.00 price target.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ryan Langston has given his Buy rating due to a combination of factors including resilient fundamentals despite temporary headwinds. He highlights that first‑quarter results were modestly below expectations mainly because of weaker seasonal respiratory volumes and severe winter weather, which suppressed admissions and emergency visits but are viewed as largely one‑time issues, with volumes normalizing later in the quarter.
He also points to solid year‑over‑year growth in revenue and adjusted EBITDA and emphasizes that management reaffirmed full‑year 2026 guidance, signaling confidence in the underlying trajectory. Incremental support from supplemental payment programs, along with a quantified but manageable headwind from health insurance exchange and Medicaid dynamics, underpins his view that earnings power remains intact, justifying a Buy rating even as the price target is revised to $500, based on a disciplined EBITDA multiple framework.
In another report released on April 24, Jefferies also maintained a Buy rating on the stock with a $525.00 price target.